FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      
           
This page is updated frequently with new Immune Diseases-related patent applications. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Diseases RSS RSS


Date/App# patent app List of recent Immune Diseases-related patents
01/22/15
20150023976
 Antibody polypeptides that antagonize cd40l patent thumbnailnew patent Antibody polypeptides that antagonize cd40l
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/15/15
20150018401
 Novel ep4 agonist patent thumbnailNovel ep4 agonist
Wherein r1 and r2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, r3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known pgi2 analogs, a selective ep4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.. .
01/15/15
20150018336
 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors patent thumbnailPyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
01/15/15
20150018329
 Pharmaceutically active pyrazolo-triazine derivatives patent thumbnailPharmaceutically active pyrazolo-triazine derivatives
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
01/15/15
20150017164
 Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease patent thumbnailCombination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease
The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.
01/15/15
20150017132
 Mesenchymal stem cells and uses therefor patent thumbnailMesenchymal stem cells and uses therefor
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl
01/08/15
20150011767
 Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints patent thumbnailUse of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints
The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010588
 Aromatic-cationic peptides and uses of same patent thumbnailAromatic-cationic peptides and uses of same
The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, and inhibition of apoptosis and necrosis to treat, prevent or ameliorate the symptoms of autoimmune diseases or condition..
Cornell University
01/01/15
20150004182
 Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases patent thumbnailPopulation of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases
The present invention relates to methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (gvhd) using populations or compositions of immunoregulatory t cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.. .
Universite Paris Est Creteil Val De Marne
01/01/15
20150004178
 Anti-human sema4a antibodies useful to treat disease patent thumbnailAnti-human sema4a antibodies useful to treat disease
Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
12/25/14
20140378475

Substituted tetrahydrocarbazole and carbazole carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378446

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
12/25/14
20140377291

Glycosphingolipids for use in modulating immune responses


Provided herein are sphingolipid compounds that are useful for activating natural killer t cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer t cells.
President And Fellows Of Harvard College
12/18/14
20140371307

Sirt 1 activator including syringaresinol


The present invention relates to a compound of formula 1, and an sirt 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the sirt 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases..
Amorepacific Corporation
12/18/14
20140371292

Method for the controlled intracellular delivery of nucleic acids


The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase.
Ludwig-maximilians-universitat Munchen
12/18/14
20140371272

Therapeutic compounds


The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
Regents Of The University Of Minnesota
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/18/14
20140371198

Novel compounds useful for the treatment of metabolic and inflammatory diseases


These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .
12/18/14
20140370044

Modified epitopes for boosting cd4+ t-cell responses


The present invention relates to immunogenic peptides comprising a t-cell epitope. Said peptides are modified such that cd4+ t-cell responses are obtainable that are much stronger than the cd4+ t-cell responses obtained with the same peptides not comprising said modification.
Life Sciences Research Partners Vzw
12/18/14
20140370033

Methods for the treatment or prevention of systemic sclerosis


The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that ssc patients have an elevated plasma level of cxcl4.
Stichting Katholieke Universiteit
12/18/14
20140369966

Preventive and/or ameliorative agent for diseases, stamina enhancement agent, anti-fatigue agent, and pharmaceutical and food and drink using them


A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria.
Tfk Co., Ltd.
12/11/14
20140364607

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
12/11/14
20140364604

Method of making monomethyl fumarate


Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis..
12/11/14
20140364438

Triazolopyridine derivatives as a tyrosine kinase inhibitor


Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
12/11/14
20140364401

Antispasmodic 1,2-diols and 1,2,3-triols


The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/11/14
20140363829

Method for increasing specificity of diagnostic tests for autoimmune diseases


Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a dfs70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed..
12/11/14
20140363514

Core-shell particle formulation for delivering multiple therapeutic agents


A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell.
12/11/14
20140363497

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/11/14
20140363450

Oxidized cardiolipin as a novel pro-inflammatory factor


Low levels of antibodies reactive with oxidised cardiolipin (oxcl) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxcl.
12/04/14
20140357690

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
12/04/14
20140357614

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor


Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .
12/04/14
20140357599

Novel urea and thiourea derivatives


The present application discloses compounds of formula (i) wherein x is ═o, ═s, ═nh, ═noh and ═no-me; a is —c(═o)—, —s(═o)2—, —c(═s)— and p(═o)(r5)—; b is, —o—, —(ch2)3-6—, and o—(ch2)2-5—; d is, —o—, —cr7r8— and —nr9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; r1 is opt.sub. Heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof.
11/27/14
20140349987

Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases


The invention provides modulators for the orphan nuclear receptor rorγ and methods for treating rorγ mediated diseases by administrating these novel rorγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of formula (1) and the enantiomers, diastereomers, n-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof..
11/27/14
20140349311

Therapeutic agent for autoimmune diseases or allergy, and screening for the therapeutic agent


Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between sema3a and a neuropilin-1/plexin-a1 heteroreceptor. The substance includes, for example, a sema3a neutralizing antibody, a neuropilin-1 neutralizing antibody, or a soluble neuropilin-1 or derivative thereof.
11/20/14
20140343150

Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases


A phytosphingosine derivative of chemical formula ia or ib, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like..
11/20/14
20140341935

Mutant hsp70i to prevent autoimmune disease


A vaccine and method of treatment suitable for treating autoimmune diseases, such as vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 dna sequence encoding the peptide..
11/20/14
20140341933

Use of pdl1 expressing cells to convert t cells into regulatory t cells


The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
11/20/14
20140341921

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..


Popular terms: [SEARCH]

Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.5377

3801

458895 - 0 - 72